<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075580</url>
  </required_header>
  <id_info>
    <org_study_id>BI-PORT</org_study_id>
    <nct_id>NCT02075580</nct_id>
  </id_info>
  <brief_title>Totally Implantable Venous Access Devices: Quality of Life and Body Image</brief_title>
  <acronym>BI-PORT</acronym>
  <official_title>Totally Implantable Venous Access Devices (TIVAD): Impact on Quality of Life and Body Image</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Guido Berlucchi ONLUS, Brescia, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that totally Implantable Venous Access Devices in neoplastic patients
      modify body image and self-representation. Therefore, the purpose of this study is to
      evaluate the efficacy of psychological intervention on patients undergone this surgical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Generic and quality of life and body image</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC (European Organization for Research and Treatment of Cancer) questionnaire:
BR23 (Breast questionnaire, used just for BI scale, that is Body Image items)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with care</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC (European Organization for Research and Treatment of Cancer) questionnaire: QLQ C30 (Quality of Life Questionnaire)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Generic and quality of life and body image</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>textual analysis of discoursive modalities used by patient in self-description</description>
  </other_outcome>
  <other_outcome>
    <measure>Generic and quality of life and body image</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC questionnaire:  IN-PATSAT32 (patient satisfaction questionnaire)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Neoplasms Undergoing Chemotherapy</condition>
  <arm_group>
    <arm_group_label>psychological support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>psychological support (interactive/cognitive strategies)</intervention_name>
    <description>cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)
metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)
psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)
questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)</description>
    <arm_group_label>psychological support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neoplastic patients

          -  adults

          -  not visible demolitive interventions

          -  not psychopathological diagnosis

          -  language understanding

        Exclusion Criteria:

          -  not neoplastic patients

          -  psychopathological diagnosis

          -  language misunderstanding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marco Sarpa, Medicine</last_name>
    <email>marcoscarpa73@yahoo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Veneto Institute of Oncology IOV-IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Scarpa, MD</last_name>
      <email>marcoscarpa73@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Pinto Eleonora, PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Castoro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Cagol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Alfieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muzio Meroni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Granziera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelo Ciccarese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Cappellato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Connie Celentano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Manfredi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annarita Di Bello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Miazzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donatella Soranzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca M Saadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Noaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Oncologico Veneto IRCCS</investigator_affiliation>
    <investigator_full_name>Marco Scarpa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>cancer, quality of life, body-image, subcutaneous-implant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
